Related Experiment Video
Updated: Aug 16, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C virus infection in HIV-infected patients
1Division of Infectious Diseases, Johns Hopkins Medical Institutions, 1830 East Monument Street, Room 319, Baltimore, MD 21287, USA. msulkows@jhmi.edu
Insights
Hepatitis C (HCV) and HIV coinfection is common, with HCV-related liver disease causing significant illness in HIV patients. Treatment with pegylated interferon-alpha plus ribavirin is safe and effective for these individuals.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection affects 15-30% of HIV-infected individuals in the US due to shared transmission routes.
- HCV-related liver disease is a leading cause of morbidity and mortality in HIV-coinfected patients, particularly with effective antiretroviral therapy (ART).
Purpose of the Study:
- To review the epidemiology, natural history, and management of HCV in patients coinfected with HIV.
- To highlight the complexities and recent advancements in treating HCV in this population.
Main Methods:
- Review of recent randomized controlled trials and guidelines from the Infectious Diseases Society of America and the American Association for the Study of Liver Disease.
- Focus on evidence regarding the safety, tolerability, and efficacy of HCV treatment in HIV-infected individuals.
Main Results:
- Pegylated interferon-alpha plus ribavirin has demonstrated safety, tolerability, and efficacy in treating HCV in HIV-infected individuals.
- Despite comorbidities and ART challenges, HCV treatment is recommended and feasible.
Conclusions:
- HCV management in HIV-coinfected patients requires careful consideration of comorbidities and ART.
- Effective HCV treatment options are now available, improving outcomes for coinfected individuals.
Abstract:
Because of shared routes of transmission, hepatitis C and HIV coinfection is common in the United States, affecting 15% to 30% of HIV-infected individuals. In the era of highly effective antiretroviral therapy, hepatitis C virus (HCV)-related liver disease has emerged as a significant cause of morbidity and mortality. Accordingly, the Infectious Diseases Society of America and the American Association for the Study of Liver Disease guidelines for the management of HCV recommend that patients with HIV/HCV undergo medical evaluation for HCV-related liver disease and consideration for HCV treatment and, if indicated, orthotopic liver transplantation. However, the treatment of patients with HIV/HCV is complicated by the relatively high prevalence of medical and psychiatric comorbidities and the challenges of anti-HCV therapy in the setting of HIV disease and antiretroviral therapy. Nonetheless, recently completed randomized controlled trials provide evidence of the safety, tolerability, and efficacy of HCV treatment with pegylated interferon-alpha plus ribavirin in HIV-infected individuals. This review focuses on the epidemiology, natural history, and management of HCV in the HIV-infected patient.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Cytomegalovirus Disease
Cryptococcal Meningitis
